Lataa...
Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis
Rationale: Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator recently approved for patients with CF age 6 and older with the G551D mutation. Objectives: To evaluate ivacaftor in a postapproval setting and determine mechanism of action and response of clinically re...
Tallennettuna:
| Julkaisussa: | Am J Respir Crit Care Med |
|---|---|
| Päätekijät: | , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Thoracic Society
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4226057/ https://ncbi.nlm.nih.gov/pubmed/24927234 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1164/rccm.201404-0703OC |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|